Segmentectomy and lobectomy confer similar overall survival (OS) and lung cancer-specific survival (LCSS) among patients with primary nonsmall cell lung cancer (NSCLC) of ≤20 mm without lymph node or distant metastasis, a recent study has shown.
There appears to be a dose-response protective effect of serum concentrations of 25-hydroxyvitamin D (25(OH)D) on the risk of breast cancer, such that levels of ≥60 ng/mL yield the most protection, according to a recent study.
Continued follow-up study of individuals at high risk of pancreatic ductal adenocarcinoma (PDAC) leads to successful detection of resectable tumours and high-grade precursor neoplasms, as shown in a recent study.
Surgical resection (SR) as a first-line treatment for small perivascular hepatocellular carcinoma (HCC) provides better long-term tumour control than radiofrequency ablation (RFA), a recent study has shown.
In metastatic triple-negative breast cancer (mTNBC) patients, the neutrophil-to-lymphocyte (NLR) and platelet-to-lymphocyte (PLR) ratios predict outcomes with platinum-based chemotherapy, according to a recent study.
Psychological interventions appear to provide minimal benefits in improving anxiety in patients with cancer, according to a recent meta-analysis. Lack of substantial distress at baseline may contribute to this effect.
The likelihood of restarting treatment with direct oral anticoagulants (DOACs) following gastrointestinal bleeding (GIB) appears to be low among older patients who require blood and intensive care, a study has shown. Furthermore, a history of venous thromboembolism and thienopyridine use are risk factors for subsequent thromboembolism and GIB, respectively.
Adding bavituximab to docetaxel in the treatment of patients with previously treated advanced nonsmall cell lung cancer (NSCLC) does not provide survival advantage, although the combination appears to be well tolerated, according to the results of a phase III study.
External beam radiotherapy (EBRT) is superior to radical prostatectomy (RP) in terms of 3-year sexual function scores in men with low-risk prostate cancer, according to a recent study. No such difference is seen in high-risk patients.